Advertisement Sagent Pharma introduces Paclitaxel Injection, USP - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Sagent Pharma introduces Paclitaxel Injection, USP

Sagent Pharmaceuticals, a US developer of pharmaceutical products, has introduced its chemotherapy drug, Paclitaxel Injection, USP.

The drug has been launched in 30mg, 100mg and 300mg latex-free, multi-dose vials.

Paclitaxel can be used alone or with other drugs as a treatment for breast cancer, ovarian cancer, non-small cell lung cancer and AIDS-related Kaposi’s sarcoma.

Sagent CEO, founder, and chairman of the board Jeffrey Yordon said the launch of paclitaxel expands their growing portfolio of injectable oncolytics to six products.